ATE252896T1 - Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs - Google Patents
Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfsInfo
- Publication number
- ATE252896T1 ATE252896T1 AT99967497T AT99967497T ATE252896T1 AT E252896 T1 ATE252896 T1 AT E252896T1 AT 99967497 T AT99967497 T AT 99967497T AT 99967497 T AT99967497 T AT 99967497T AT E252896 T1 ATE252896 T1 AT E252896T1
- Authority
- AT
- Austria
- Prior art keywords
- pcdfs
- alkyl
- tamoxifen
- breast cancer
- combined treatment
- Prior art date
Links
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 title abstract 4
- 229960001603 tamoxifen Drugs 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 238000009261 endocrine therapy Methods 0.000 title 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical class C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 tamoxifen Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/217,780 US6136845A (en) | 1998-12-21 | 1998-12-21 | Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl PCDFs |
| PCT/US1999/030554 WO2000037065A2 (en) | 1998-12-21 | 1999-12-21 | Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE252896T1 true ATE252896T1 (de) | 2003-11-15 |
Family
ID=22812479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99967497T ATE252896T1 (de) | 1998-12-21 | 1999-12-21 | Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6136845A (de) |
| EP (1) | EP1140047B1 (de) |
| JP (1) | JP2002532546A (de) |
| AT (1) | ATE252896T1 (de) |
| AU (1) | AU772920B2 (de) |
| CA (1) | CA2356624A1 (de) |
| DE (1) | DE69912477T2 (de) |
| ES (1) | ES2207981T3 (de) |
| WO (1) | WO2000037065A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709520B2 (en) | 2000-10-06 | 2010-05-04 | The Texas A&M University System | Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers |
| EP1675843A1 (de) * | 2003-10-14 | 2006-07-05 | Council of Scientific and Industrial Research | (3r, 4r) -trans-3,4-diarylchroman derivaten mit oestroger wirkung |
| CN1318411C (zh) * | 2005-03-21 | 2007-05-30 | 中国海洋大学 | 氢化轮枝霉酮类化合物及其制备方法和用途 |
| US9517240B2 (en) | 2006-09-26 | 2016-12-13 | The Regents Of The University Of California | Methods and compositions for cancer prevention and treatment |
| WO2008039482A2 (en) * | 2006-09-26 | 2008-04-03 | The Regents Of The University Of California | Methods and compositions for cancer prevention and treatment |
| WO2009055734A1 (en) * | 2007-10-26 | 2009-04-30 | Acadia Pharmaceuticals Inc. | Condensed compounds with activity at estrogen receptors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656187A (en) * | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
| US5516790A (en) * | 1989-01-23 | 1996-05-14 | Texas A&M University System Technology Licensing Office | Synthesis and application of alkyl-substituted dibenzofurans as antitumorigenic agents |
| US5604248A (en) * | 1994-05-05 | 1997-02-18 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
-
1998
- 1998-12-21 US US09/217,780 patent/US6136845A/en not_active Expired - Fee Related
-
1999
- 1999-12-21 AU AU23766/00A patent/AU772920B2/en not_active Ceased
- 1999-12-21 CA CA002356624A patent/CA2356624A1/en not_active Abandoned
- 1999-12-21 DE DE69912477T patent/DE69912477T2/de not_active Expired - Fee Related
- 1999-12-21 ES ES99967497T patent/ES2207981T3/es not_active Expired - Lifetime
- 1999-12-21 JP JP2000589176A patent/JP2002532546A/ja not_active Withdrawn
- 1999-12-21 EP EP99967497A patent/EP1140047B1/de not_active Expired - Lifetime
- 1999-12-21 WO PCT/US1999/030554 patent/WO2000037065A2/en not_active Ceased
- 1999-12-21 AT AT99967497T patent/ATE252896T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002532546A (ja) | 2002-10-02 |
| EP1140047A2 (de) | 2001-10-10 |
| DE69912477D1 (de) | 2003-12-04 |
| AU2376600A (en) | 2000-07-12 |
| US6136845A (en) | 2000-10-24 |
| ES2207981T3 (es) | 2004-06-01 |
| EP1140047B1 (de) | 2003-10-29 |
| WO2000037065A2 (en) | 2000-06-29 |
| WO2000037065A3 (en) | 2000-09-14 |
| DE69912477T2 (de) | 2004-08-19 |
| AU772920B2 (en) | 2004-05-13 |
| CA2356624A1 (en) | 2000-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE331534T1 (de) | Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs | |
| AU5338301A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| SI1472541T1 (sl) | Prikazovalni agensi in postopek prikazovanja naaladase ali psma | |
| DE60112974D1 (en) | Carbolinderivate | |
| MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
| BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
| MXPA04003674A (es) | Uso mejorado de compuesto antitumoral en terapia de cancer. | |
| WO2003087831A3 (en) | Proteins involved in breast cancer | |
| AU5338401A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| AR052774A1 (es) | Inmunoterapia para trastornos autoinmunes | |
| BR0010702A (pt) | Novas quinonas como terapias de doenças | |
| DE60216233D1 (en) | Carbolinderivate | |
| BR9912327A (pt) | Inibidores da uroquinase | |
| SE9802208D0 (sv) | Novel compounds | |
| SE9903997D0 (sv) | New compounds | |
| ATE252896T1 (de) | Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs | |
| MXPA03011270A (es) | Uso de antagonistas rank para tratar cancer. | |
| TR200101693T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
| SE9802209D0 (sv) | Novel compounds | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
| DE50211672D1 (de) | Urokinase-inhibitoren | |
| PL365279A1 (en) | Biotin-derivates and their conjugates with chelating agents | |
| ATE366720T1 (de) | Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose | |
| ATE329597T1 (de) | Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |